Biofrontera Bioscience GmbH
7 clinical trials · Sponsor
◉ Watch Biofrontera Bioscience GmbH
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp (NCT05060237) | Biofrontera Bioscience GmbH | 2021-12-01 |
| Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK) (NCT04319159) | Biofrontera Bioscience GmbH | 2020-03-05 |
Track Biofrontera Bioscience GmbH automatically
Every clearance here is in the API, with alerts when new ones post.